Sorafenib (Nexavar®)

print version

Sorafenib belongs to the small molecule receptor tyrosine kinase inhibitor drug class. It is marketed by Bayer under the name Nexavar for use in kidney and liver cancer. It is adminstered as a single agent to prolong survival rates in cancer patients. The mechanism of action of sorafenib targets VEGF receptors 2-3, KIT, RET, Raf and PDGFR. As a result is associated with side effects such as hypothyroidism, hypertension and proteinuria. Severe skin/hand complaints such as hand/foot syndrome (a condition where blisters appear on the palms and soles) and alopecia have been reported in sorafenib patients.